ストックスクリーナーアプリを入手
41.58
1.61%
-0.68
アフターアワーズ：
41.58
前日終値:
$42.26
開ける：
$41.91
24時間の取引高:
3.16M
Relative Volume:
1.33
時価総額：
$8.22B
収益：
$2.69B
当期純損益:
$-214.04M
株価収益率:
-35.54
EPS:
-1.17
ネットキャッシュフロー:
$98.43M
1週間 パフォーマンス:
-4.94%
1か月 パフォーマンス:
-7.97%
6か月 パフォーマンス:
-39.94%
1年 パフォーマンス:
-34.23%
1日の値動き範囲:
$40.83
$42.81
1週間の範囲:
$40.83
$45.30
52週間の値動き範囲:
$39.97
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
EXAS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
41.58 | 8.22B | 2.69B | -214.04M | 98.43M | -1.17 |
|
TMO
Thermo Fisher Scientific Inc
|
427.50 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
186.83 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
411.49 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
102.48 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
143.91 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-03-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | 開始されました | Barclays | Overweight |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-27 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-01-02 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-10-10 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-08-02 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-05-10 | アップグレード | Craig Hallum | Hold → Buy |
| 2023-05-05 | 開始されました | UBS | Neutral |
| 2023-03-09 | アップグレード | Citigroup | Neutral → Buy |
| 2023-02-10 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | ダウングレード | Craig Hallum | Buy → Hold |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-06-03 | 開始されました | Piper Sandler | Neutral |
| 2021-11-03 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | 繰り返されました | BTIG Research | Buy |
| 2021-07-29 | 繰り返されました | Canaccord Genuity | Buy |
| 2021-07-29 | 繰り返されました | Oppenheimer | Outperform |
| 2021-07-29 | 繰り返されました | Stifel | Buy |
| 2021-06-15 | 開始されました | Raymond James | Strong Buy |
| 2021-06-03 | 開始されました | Goldman | Buy |
| 2021-05-25 | 開始されました | Wells Fargo | Equal Weight |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2020-10-29 | ダウングレード | UBS | Buy → Neutral |
| 2020-10-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-10-08 | 再開されました | BTIG Research | Buy |
| 2020-04-02 | 開始されました | Evercore ISI | Outperform |
| 2020-01-10 | 再開されました | BTIG Research | Buy |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2019-12-13 | 開始されました | Dougherty & Company | Buy |
| 2019-11-15 | 開始されました | Stifel | Buy |
| 2019-10-17 | 繰り返されました | BofA/Merrill | Buy |
| 2019-10-01 | 再開されました | Craig Hallum | Buy |
| 2019-09-26 | 開始されました | Oppenheimer | Outperform |
| 2019-02-26 | アップグレード | Goldman | Neutral → Buy |
| 2018-10-09 | 開始されました | UBS | Buy |
| 2018-09-05 | 再開されました | The Benchmark Company | Hold |
| 2018-08-13 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-04-03 | アップグレード | BTIG Research | Neutral → Buy |
| 2018-01-29 | 開始されました | Goldman | Neutral |
| 2018-01-08 | 繰り返されました | The Benchmark Company | Buy |
| 2017-11-13 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | ダウングレード | BTIG Research | Buy → Neutral |
すべてを表示
Exact Sciences Corp (EXAS) 最新ニュース
Market Sentiment Around Loss-Making Exact Sciences Corporation (NASDAQ:EXAS) - simplywall.st
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers - Yahoo Finance
Exact Sciences (EXAS) Validates Oncotype DX Test for Diverse Bre - GuruFocus
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups - The Joplin Globe
Deep Dive Into Exact Sciences Stock: Analyst Perspectives (8 Ratings) - Benzinga
Mizuho Initiates Exact Sciences at Outperform With $60 Price Target - marketscreener.com
Mizuho sets $60 target on Exact Sciences stock, sees outperform - Investing.com
Mizuho sets $60 target on Exact Sciences stock, sees outperform By Investing.com - Investing.com UK
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
10 Promising Biotech Stocks to Invest in (April 2025) - Securities.io
Exact Sciences Schedules First Quarter 2025 Earnings Call - The Joplin Globe
Cancer Screening Leader Exact Sciences Sets Q1 2025 Earnings Date: Key Details Inside - Stock Titan
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening - BioSpace
Benchmark maintains Buy on Exact Sciences, price target at $65 By Investing.com - Investing.com South Africa
Benchmark maintains Buy on Exact Sciences, price target at $65 - Investing.com
Exact Sciences Positioned for Growth with Upcoming Product Launches and Margin Expansion - TipRanks
High Growth Tech Stocks To Watch In The US March 2025 - Yahoo Finance
Should You Retain Exact Sciences Stock in Your Portfolio Now? - Yahoo Finance
Why Exact Sciences Corporation (EXAS) is Among the Best Diagnostics Stocks to Invest in Right Now - Insider Monkey
12 Best Diagnostics Stocks to Invest In Right Now - Insider Monkey
Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Should You Invest in Exact Sciences Corp. (EXAS)? - MSN
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN - Quantisnow
Former Exact Sciences COO Joins Sera Prognostics Board Amid Strategic Expansion - Stock Titan
"Pick Up Your Poop" F Cancer's New Campaign Encourages At-Home Colorectal Cancer Screening - WV News
RBC Capital Initiates Coverage of Exact Sciences (BMV:EXAS) with Sector Perform Recommendation - Nasdaq
Commit To Buy EXACT Sciences At $30, Earn 14% Using Options - Nasdaq
Expert Outlook: Exact Sciences Through The Eyes Of 7 Analysts - Benzinga
PreventionGenetics Assumes the Management of Sponsored Genetic Testing Program for Three Rare Genetic Diseases: Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1 & Hereditary ATTR Amyloidosis - Business Wire
Exact Sciences initiated with a Sector Perform at RBC Capital - TipRanks
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner - Joplin Globe
Exact Sciences Triples Industry Average in Employee Engagement, Wins Prestigious Gallup Award - StockTitan
New Data Highlight the Positive Impact of Exact Sciences’ Oncotype DX - Business Wire
Charles Schwab Investment Management Inc. Grows Holdings in Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Exact Sciences Co. (NASDAQ:EXAS) Stake Increased by Jones Financial Companies Lllp - Defense World
3 Top Cancer Biotechs to Keep An Eye On in 2025 - Yahoo Finance
Exact Sciences at Raymond James Conference: Strategic Growth and Innovation - Investing.com
Cancer Biomarkers Research Report 2024: Global Market Projected to Soar to USD 62.14 Billion by 2034, Driven by Technological Advancements and Increasing Demand for Early Detection - GlobeNewswire Inc.
La Paloma CC: Set to host PGA Tour Champions' Cologuard Classic - The First Call
Here’s What Led Artisan Mid Cap Fund to Trim Exact Sciences Corporation (EXAS) - Yahoo Finance
Exact Sciences Corporation (EXAS): Among the Cash-Rich Mid Cap Stocks to Buy Now - Insider Monkey
Truist Financial Corp Sells 1,905 Shares of Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Exact Sciences Co. (NASDAQ:EXAS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
EXACT Sciences Corp. to Host Earnings Call - ACCESS Newswire
Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by New York State Common Retirement Fund - MarketBeat
Atria Wealth Solutions Inc. Takes $316,000 Position in Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Heritage Investors Management Corp Has $4.29 Million Stake in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Generali Investments Towarzystwo Funduszy Inwestycyjnych Acquires 6,000 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by Sanctuary Advisors LLC - Defense World
Exact Sciences (NASDAQ:EXAS) Price Target Cut to $70.00 by Analysts at Piper Sandler - MarketBeat
Exact Sciences Corp (EXAS) 財務データ
収益
当期純利益
現金流量
EPS
0.41%
大文字化:
|
ボリューム (24 時間):